60¢sixtycents

Amgen Inc.AMGN

$337.60-4.06 (-1.19%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$184B
Large-cap
+57%
2016 — today
10-Year Price
+120%
2016 — today
52-Week Range
$271.18$388.16
Current $337.60· 57%

Amgen (est. 1980, Thousand Oaks, CA) discovers, develops, and manufactures human therapeutics across oncology, hematology, inflammation, bone health, cardiovascular disease, nephrology, and neuroscience. Its portfolio includes Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, KYPROLIS, and Repatha. Amgen distributes globally to healthcare providers via wholesalers and direct channels. The firm maintains strategic R&D alliances with partners including Novartis, UCB, BeiGene, and Eli Lilly to advance clinical pipelines.

Valuation in context

P/E ratio
23.5
Above average
Pricier than usual over the last 10 years
P/B ratio
20.0
Above average
Pricier than usual over the last 10 years
EV / EBITDA
13.7
Historically pricey
Historically pricey — last 10 years
Dividend Yield
2.9%
Above average
Above the 10-year average
PEG ratio
6.6
Historically pricey
Historically pricey — last 10 years
FCF Yield
4.7%
Historically low
Historically low relative to the last 10 years
Free · No credit card needed

Get alerted when AMGN is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.